157 lines
No EOL
28 KiB
XML
157 lines
No EOL
28 KiB
XML
<?xml version="1.0" encoding="utf-8"?>
|
||
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
|
||
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
|
||
|
||
<head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
|
||
<!-- AppResources meta begin -->
|
||
<meta name="paf-app-resources" content="" />
|
||
<script type="text/javascript">var ncbi_startTime = new Date();</script>
|
||
|
||
<!-- AppResources meta end -->
|
||
|
||
<!-- TemplateResources meta begin -->
|
||
<meta name="paf_template" content="" />
|
||
|
||
<!-- TemplateResources meta end -->
|
||
|
||
<!-- Logger begin -->
|
||
<meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-table" /><meta name="ncbi_acc" content="NBK578045" /><meta name="ncbi_domain" content="niceng136er3" /><meta name="ncbi_report" content="objectonly" /><meta name="ncbi_type" content="table" /><meta name="ncbi_objectid" content="ch3.appa.tab1" /><meta name="ncbi_pcid" content="/NBK578045/table/ch3.appa.tab1/?report=objectonly" /><meta name="ncbi_app" content="bookshelf" />
|
||
<!-- Logger end -->
|
||
|
||
<title>Table 11, Review protocol: Initiating treatment - Evidence review for initiating treatment - NCBI Bookshelf</title>
|
||
|
||
<!-- AppResources external_resources begin -->
|
||
<link rel="stylesheet" href="/core/jig/1.15.2/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.15.2/js/jig.min.js"></script>
|
||
|
||
<!-- AppResources external_resources end -->
|
||
|
||
<!-- Page meta begin -->
|
||
<meta name="robots" content="NOINDEX,NOFOLLOW,NOARCHIVE,NOIMAGEINDEX" /><meta name="author" content="National Guideline Centre (UK)" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Table 11, Review protocol: Initiating treatment" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="National Institute for Health and Care Excellence (NICE)" /><meta name="DC.Contributor" content="National Guideline Centre (UK)" /><meta name="DC.Date" content="2019/08" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK578045/table/ch3.appa.tab1/" /><meta name="bk-non-canon-loc" content="/books/n/niceng136er3/toc/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK578045/table/ch3.appa.tab1/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace} .first-line-outdent .bk_ref {display: inline} .body-content h2, .body-content .h2 {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list .graphic {display:inline-block !important} .temp-labeled-list img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js?_=3.18"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.26/books.min.js"> </script>
|
||
|
||
<!-- Page meta end -->
|
||
<link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8D78EB7D72E7F100000000010E00D6.m_5" />
|
||
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4216701/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/3984801/12930/3964959.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3411343/3882866.css" media="print" /></head>
|
||
<body class="book-table">
|
||
<div class="grid no_max_width">
|
||
<div class="col twelve_col nomargin shadow">
|
||
<!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
|
||
<div class="sysmessages">
|
||
<noscript>
|
||
<p class="nojs">
|
||
<strong>Warning:</strong>
|
||
The NCBI web site requires JavaScript to function.
|
||
<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
|
||
</p>
|
||
</noscript>
|
||
</div>
|
||
<!--/.sysmessage-->
|
||
<div class="wrap">
|
||
<div class="page">
|
||
<div class="top">
|
||
|
||
<div class="header">
|
||
|
||
|
||
</div>
|
||
|
||
|
||
|
||
<!--<component id="Page" label="headcontent"/>-->
|
||
|
||
</div>
|
||
<div class="content">
|
||
<!-- site messages -->
|
||
<div class="container content">
|
||
<div class="object">
|
||
|
||
<div class="main-content lit-style"><div class="body-content whole_rhythm"><div id="ch3.appa.tab1" class="table"><h3><span class="label">Table 11</span><span class="title">Review protocol: Initiating treatment</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK578045/table/ch3.appa.tab1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch3.appa.tab1_lrgtbl__"><table><thead><tr><th id="hd_h_ch3.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Field</th><th id="hd_h_ch3.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Content</th></tr></thead><tbody><tr><td headers="hd_h_ch3.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Review question</td><td headers="hd_h_ch3.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">At what blood pressure and/or cardiovascular disease risk threshold should antihypertensive drug treatment be initiated for adults with hypertension?</td></tr><tr><td headers="hd_h_ch3.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Type of review question</td><td headers="hd_h_ch3.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>Intervention review</p>
|
||
<p>A review of health economic evidence related to the same review question was conducted in parallel with this review. For details, see the health economic review protocol for this NICE guideline.</p>
|
||
</td></tr><tr><td headers="hd_h_ch3.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Objective of the review</td><td headers="hd_h_ch3.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">To establish which blood pressure or cardiovascular disease risk threshold antihypertensive drug treatment should be initiated at.</td></tr><tr><td headers="hd_h_ch3.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Eligibility criteria – population / disease / condition / issue / domain</td><td headers="hd_h_ch3.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>Population: Adults (over 18 years) who are not on current pharmacological treatment for hypertension (minimum wash-out 4 weeks)</p>
|
||
<p>Stratify by:
|
||
<ul id="ch3.l9"><li id="ch3.lt30" class="half_rhythm"><div>Presence or absence of type 2 diabetes</div></li><li id="ch3.lt31" class="half_rhythm"><div>Cardiovascular or blood pressure baseline risk</div></li></ul></p>
|
||
</td></tr><tr><td headers="hd_h_ch3.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Eligibility criteria – intervention(s) / exposure(s) / prognostic factor(s)</td><td headers="hd_h_ch3.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Treatment initiation at different thresholds
|
||
<ul id="ch3.l10"><li id="ch3.lt32" class="half_rhythm"><div>Systolic blood pressure targets:
|
||
<ul id="ch3.l11" class="circle"><li id="ch3.lt33" class="half_rhythm"><div>Below120</div></li><li id="ch3.lt34" class="half_rhythm"><div>120–129</div></li><li id="ch3.lt35" class="half_rhythm"><div>130–139 mmHg</div></li><li id="ch3.lt36" class="half_rhythm"><div>140–59 mmHg</div></li><li id="ch3.lt37" class="half_rhythm"><div>160 mmHg or above</div></li></ul></div></li><li id="ch3.lt38" class="half_rhythm"><div>Diastolic blood pressure targets:
|
||
<ul id="ch3.l12" class="circle"><li id="ch3.lt39" class="half_rhythm"><div><80 mmHg</div></li><li id="ch3.lt40" class="half_rhythm"><div>80–84 mmHg</div></li><li id="ch3.lt41" class="half_rhythm"><div>85–89 mmHg</div></li><li id="ch3.lt42" class="half_rhythm"><div>90–94 mmHg</div></li><li id="ch3.lt43" class="half_rhythm"><div>95 mmHg or above</div></li></ul></div></li></ul>
|
||
Cardiovascular risk thresholds:
|
||
<ol id="ch3.l13"><li id="ch3.lt44" class="half_rhythm"><div>5–9%</div></li><li id="ch3.lt45" class="half_rhythm"><div>10–14%</div></li><li id="ch3.lt46" class="half_rhythm"><div>15–19%</div></li><li id="ch3.lt47" class="half_rhythm"><div>Above 20%</div></li></ol>
|
||
Data will be preferentially extracted if they compare across or within these categories; however, other comparisons will be considered in the absence of this.</td></tr><tr><td headers="hd_h_ch3.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Eligibility criteria – comparator(s) / control or reference (gold) standard</td><td headers="hd_h_ch3.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>Compared against each other (comparing different blood pressure and/or cardiovascular risk thresholds)</p>
|
||
<p>Also within each other</p>
|
||
</td></tr><tr><td headers="hd_h_ch3.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Outcomes and prioritisation</td><td headers="hd_h_ch3.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>All outcomes to be measured at a minimum of 12 months. Where multiple time points are reported within each study, the longest time point only will be extracted.</p>
|
||
<p><b>Critical</b>
|
||
<ul id="ch3.l14"><li id="ch3.lt48" class="half_rhythm"><div>All-cause mortality</div></li><li id="ch3.lt49" class="half_rhythm"><div>Health-related quality of life</div></li><li id="ch3.lt50" class="half_rhythm"><div>Stroke (ischaemic or haemorrhagic)</div></li><li id="ch3.lt51" class="half_rhythm"><div>Myocardial infarction</div></li></ul>
|
||
<b>Important</b>
|
||
<ul id="ch3.l15"><li id="ch3.lt52" class="half_rhythm"><div>Heart failure needing hospitalisation</div></li><li id="ch3.lt53" class="half_rhythm"><div>Vascular procedures (including lower limb, coronary and carotid artery procedures)</div></li><li id="ch3.lt54" class="half_rhythm"><div>Angina needing hospitalisation</div></li><li id="ch3.lt55" class="half_rhythm"><div>Side effect 1: Acute kidney injury</div></li><li id="ch3.lt56" class="half_rhythm"><div>Side effect 2: New onset diabetes</div></li><li id="ch3.lt57" class="half_rhythm"><div>Side effect 3: Treatment related admission</div></li><li id="ch3.lt58" class="half_rhythm"><div>Side effect 4: Hypotension (dizziness)</div></li><li id="ch3.lt59" class="half_rhythm"><div>[Combined cardiovascular disease outcomes in the absence of MI and stroke data]</div></li><li id="ch3.lt60" class="half_rhythm"><div>[Coronary heart disease outcome in the absence of MI data]</div></li></ul></p>
|
||
</td></tr><tr><td headers="hd_h_ch3.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Eligibility criteria – study design</td><td headers="hd_h_ch3.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<ol id="ch3.l16"><li id="ch3.lt61" class="half_rhythm"><div>SRs (including IPD analyses) and RCTs that stratify or subgroup by baseline cardiovascular risk or blood pressure</div></li><li id="ch3.lt62" class="half_rhythm"><div>Non-randomised studies that stratify by baseline cardiovascular risk or blood pressure</div></li></ol>
|
||
<ul id="ch3.l17"><li id="ch3.lt63" class="half_rhythm"><div>Confounders that should be adjusted for:
|
||
<ul id="ch3.l18" class="circle"><li id="ch3.lt64" class="half_rhythm"><div>age</div></li><li id="ch3.lt65" class="half_rhythm"><div>prior CV event</div></li><li id="ch3.lt66" class="half_rhythm"><div>smoking</div></li><li id="ch3.lt67" class="half_rhythm"><div>sex</div></li><li id="ch3.lt68" class="half_rhythm"><div>BP (CV risk)</div></li></ul></div></li></ul>
|
||
Note:
|
||
<ul id="ch3.l19"><li id="ch3.lt69" class="half_rhythm"><div>Treatment must be received for a minimum of 1 year in study</div></li><li id="ch3.lt70" class="half_rhythm"><div>Where an IPD meta-analysis is available that matches the protocol, this will be included and data published since will be presented separately. IPD meta-analysis is considered the highest quality evidence, therefore lower quality evidence will only be considered if it was published after the IPD.</div></li></ul></td></tr><tr><td headers="hd_h_ch3.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Other inclusion exclusion criteria</td><td headers="hd_h_ch3.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Exclusions:
|
||
<ul id="ch3.l20"><li id="ch3.lt71" class="half_rhythm"><div>Non-comparative data where all participants start at the same treatment threshold (studies that do not stratify by 2 or more blood pressure or CV risk groups)</div></li><li id="ch3.lt72" class="half_rhythm"><div>Studies including participants with type 1 diabetes or chronic kidney disease (A3 [heavy proteinuria]) or A2 or above for participants with type 2 diabetes.</div></li><li id="ch3.lt73" class="half_rhythm"><div>Indirect populations with secondary causes of hypertension such as tumours or structural vascular defects (Conn’s adenoma, phaeochromocytoma, renovascular hypertension).</div></li><li id="ch3.lt74" class="half_rhythm"><div>Pregnant women.</div></li><li id="ch3.lt75" class="half_rhythm"><div>Children (under 18 years).</div></li></ul></td></tr><tr><td headers="hd_h_ch3.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Proposed sensitivity / subgroup analysis, or meta-regression</td><td headers="hd_h_ch3.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No subgroups identified. The committee agreed that the stratification and adjustments required by this protocol encompassed the relevant confounding factors.</td></tr><tr><td headers="hd_h_ch3.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Selection process – duplicate screening / selection / analysis</td><td headers="hd_h_ch3.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>Duplicate screening, selection and analysis will be undertaken on this review.</p>
|
||
<p>A senior research fellow will undertake quality assurance prior to completion.</p>
|
||
</td></tr><tr><td headers="hd_h_ch3.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Data management (software)</td><td headers="hd_h_ch3.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>Pairwise meta-analyses were performed using Cochrane Review Manager (RevMan5).</p>
|
||
<p>GRADEpro was used to assess the quality of evidence for each outcome.</p>
|
||
<p>Endnote for bibliography, citations, sifting and reference management.</p>
|
||
</td></tr><tr><td headers="hd_h_ch3.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Information sources – databases and dates</td><td headers="hd_h_ch3.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>Medline, Embase, the Cochrane Library</p>
|
||
<p>Date cut off: 2000 (restrict to papers published after this date)</p>
|
||
<p>Language: Restrict to English only</p>
|
||
<p>Key papers:</p>
|
||
<p>Cochrane review (2017): <a href="http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010316.pub2/full" target="mainwindow" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">http:<wbr style="display:inline-block"></wbr>//onlinelibrary<wbr style="display:inline-block"></wbr>.wiley.com/doi/10.1002/14651858<wbr style="display:inline-block"></wbr>.CD010316.pub2/full</a></p>
|
||
</td></tr><tr><td headers="hd_h_ch3.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Identify if an update</td><td headers="hd_h_ch3.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Yes, 2011</td></tr><tr><td headers="hd_h_ch3.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Author contacts</td><td headers="hd_h_ch3.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<a href="https://www.nice.org.uk/guidance/cg127" target="mainwindow" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">https://www<wbr style="display:inline-block"></wbr>.nice.org.uk/guidance/cg127</a>
|
||
</td></tr><tr><td headers="hd_h_ch3.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Highlight if amendment to previous protocol</td><td headers="hd_h_ch3.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">For details, please see section 4.5 of <a href="https://www.nice.org.uk/article/pmg20/chapter/4-Developing-review-questions-and-planning-the-evidence-review#planning-the-evidence-review" target="mainwindow" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Developing NICE guidelines: the manual</a>.</td></tr><tr><td headers="hd_h_ch3.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Search strategy – for 1 database</td><td headers="hd_h_ch3.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">For details, please see <a href="/books/NBK578045/#ch3.appd" target="mainwindow">appendix B</a></td></tr><tr><td headers="hd_h_ch3.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Data collection process – forms / duplicate</td><td headers="hd_h_ch3.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">A standardised evidence table format will be used, and published as <a href="/books/NBK578045/#ch3.appd" target="mainwindow">appendix D</a> of the evidence report.</td></tr><tr><td headers="hd_h_ch3.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Data items – define all variables to be collected</td><td headers="hd_h_ch3.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">For details, please see evidence tables in <a href="/books/NBK578045/#ch3.appd" target="mainwindow">Appendix D</a> (clinical evidence tables) or <a href="/books/NBK578045/#ch3.apph" target="mainwindow">H</a> (health economic evidence tables).</td></tr><tr><td headers="hd_h_ch3.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Methods for assessing bias at outcome / study level</td><td headers="hd_h_ch3.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>Standard study checklists were used to appraise individual studies critically. For details, please see section 6.2 of <a href="https://www.nice.org.uk/article/pmg20/chapter/6-Reviewing-research-evidence#assessing-the-quality-of-the-evidence" target="mainwindow" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Developing NICE guidelines: the manual</a></p>
|
||
<p>The risk of bias across all available evidence was evaluated for each outcome using an adaptation of the ‘Grading of Recommendations Assessment, Development and Evaluation (GRADE) toolbox’ developed by the international GRADE working group <a href="http://www.gradeworkinggroup.org/" target="mainwindow" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">http://www<wbr style="display:inline-block"></wbr>.gradeworkinggroup.org/</a></p>
|
||
</td></tr><tr><td headers="hd_h_ch3.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Criteria for quantitative synthesis</td><td headers="hd_h_ch3.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">For details, please see section 6.4 of <a href="https://www.nice.org.uk/article/pmg20/chapter/6-Reviewing-research-evidence#assessing-the-quality-of-the-evidence" target="mainwindow" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Developing NICE guidelines: the manual</a>.</td></tr><tr><td headers="hd_h_ch3.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Methods for quantitative analysis – combining studies and exploring (in)consistency</td><td headers="hd_h_ch3.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">For details, please see the separate Methods report for this guideline.</td></tr><tr><td headers="hd_h_ch3.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Meta-bias assessment – publication bias, selective reporting bias</td><td headers="hd_h_ch3.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">For details, please see section 6.2 of <a href="https://www.nice.org.uk/article/pmg20/chapter/6-Reviewing-research-evidence#assessing-the-quality-of-the-evidence" target="mainwindow" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Developing NICE guidelines: the manual</a>.</td></tr><tr><td headers="hd_h_ch3.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Confidence in cumulative evidence</td><td headers="hd_h_ch3.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">For details, please see sections 6.4 and 9.1 of <a href="https://www.nice.org.uk/article/pmg20/chapter/1-Introduction-and-overview" target="mainwindow" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Developing NICE guidelines: the manual</a>.</td></tr><tr><td headers="hd_h_ch3.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Rationale / context – what is known</td><td headers="hd_h_ch3.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">For details, please see the introduction to the evidence review.</td></tr><tr><td headers="hd_h_ch3.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Describe contributions of authors and guarantor</td><td headers="hd_h_ch3.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>A <a href="https://www.nice.org.uk/guidance/indevelopment/gid-ng10054/documents" target="mainwindow" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">multidisciplinary committee</a> developed the evidence review. The committee was convened by the National Guideline Centre (NGC) and chaired by Anthony Wierzbicki in line with section 3 of <a href="https://www.nice.org.uk/article/pmg20/chapter/1%20Introduction%20and%20overview" target="mainwindow" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Developing NICE guidelines: the manual</a>.</p>
|
||
<p>Staff from NGC undertook systematic literature searches, appraised the evidence, conducted meta-analysis and cost-effectiveness analysis where appropriate, and drafted the evidence review in collaboration with the committee. For details, please see <a href="https://www.nice.org.uk/article/pmg20/chapter/1-Introduction-and-overview" target="mainwindow" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Developing NICE guidelines: the manual</a>.</p>
|
||
</td></tr><tr><td headers="hd_h_ch3.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Sources of funding / support</td><td headers="hd_h_ch3.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NGC is funded by NICE and hosted by the Royal College of Physicians.</td></tr><tr><td headers="hd_h_ch3.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Name of sponsor</td><td headers="hd_h_ch3.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NGC is funded by NICE and hosted by the Royal College of Physicians.</td></tr><tr><td headers="hd_h_ch3.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Roles of sponsor</td><td headers="hd_h_ch3.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NICE funds NGC to develop guidelines for those working in the NHS, public health and social care in England.</td></tr><tr><td headers="hd_h_ch3.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PROSPERO registration number</td><td headers="hd_h_ch3.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not registered</td></tr></tbody></table></div></div></div></div>
|
||
<div class="post-content"><div><p>From: <a href="/books/NBK578045/" target="mainwindow">Evidence review for initiating treatment</a></p><div class="iconblock clearfix ten_col"><a class="img_link icnblk_img" title="Table of Contents Page" href="/books/n/niceng136er3/" target="mainwindow"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-niceng136er3-lrg.png" alt="Cover of Evidence review for initiating treatment" height="100px" width="80px" /></a><div class="icnblk_cntnt"><div><div>Evidence review for initiating treatment: Hypertension in adults: diagnosis and management: Evidence review C.</div><div class="series-statement">NICE Guideline, No. 136.</div><div>National Guideline Centre (UK).</div><div>London: <a href="https://www.nice.org.uk" target="mainwindow" ref="pagearea=content-footer&targetsite=external&targetcat=link&targettype=publisher">National Institute for Health and Care Excellence (NICE)</a>; 2019 Aug.</div></div></div></div><div class="half_rhythm"><a href="/books/about/copyright/" target="mainwindow">Copyright</a> © NICE 2019.</div><p>NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p></div></div>
|
||
|
||
</div>
|
||
</div>
|
||
</div>
|
||
<div class="bottom">
|
||
|
||
<div id="NCBIFooter_dynamic">
|
||
<!--<component id="Breadcrumbs" label="breadcrumbs"/>
|
||
<component id="Breadcrumbs" label="helpdesk"/>-->
|
||
|
||
</div>
|
||
|
||
<script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js"> </script>
|
||
</div>
|
||
</div>
|
||
<!--/.page-->
|
||
</div>
|
||
<!--/.wrap-->
|
||
</div><!-- /.twelve_col -->
|
||
</div>
|
||
<!-- /.grid -->
|
||
|
||
<span class="PAFAppResources"></span>
|
||
|
||
<!-- BESelector tab -->
|
||
|
||
|
||
|
||
<noscript><img alt="statistics" src="/stat?jsdisabled=true&ncbi_db=books&ncbi_pdid=book-table&ncbi_acc=NBK578045&ncbi_domain=niceng136er3&ncbi_report=objectonly&ncbi_type=table&ncbi_objectid=ch3.appa.tab1&ncbi_pcid=/NBK578045/table/ch3.appa.tab1/?report=objectonly&ncbi_app=bookshelf" /></noscript>
|
||
|
||
|
||
<!-- usually for JS scripts at page bottom -->
|
||
<!--<component id="PageFixtures" label="styles"></component>-->
|
||
|
||
|
||
<!-- CE8B5AF87C7FFCB1_0191SID /projects/books/PBooks@9.11 portal106 v4.1.r689238 Tue, Oct 22 2024 16:10:51 -->
|
||
<span id="portal-csrf-token" style="display:none" data-token="CE8B5AF87C7FFCB1_0191SID"></span>
|
||
|
||
<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/js/3879255/4121861/3501987/4008961/3893018/3821238/3400083/3426610.js" snapshot="books"></script></body>
|
||
</html> |